Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China - Takeaways - MDSpire

Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China

  • By

  • Wei Jiang

  • Wei Zhong

  • Jingdi Yu

  • Yufei Tang

  • Qunyi Guo

  • June 18, 2026

  • 0 min

Share

  • 1

    The study analyzed 34 patients with relapsed/refractory multiple myeloma treated with KPd in China from October 2022 to December 2024.

  • 2

    The overall response rate for the KPd regimen was 82.4%, significantly influenced by high-risk cytogenetics and prior daratumumab exposure.

  • 3

    The median progression-free survival was 13 months, with a 2-year progression-free survival rate of 40.3% among the patients.

  • 4

    Hematologic toxicities were the most common adverse events, occurring in 73.5% of patients, with 58.8% experiencing grade 3/4 adverse events.

  • 5

    KPd demonstrated substantial effectiveness in heavily pretreated Chinese RRMM patients, but careful monitoring for toxicities is essential.

Original Source(s)

Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China

  • by Wei Jiang, Wei Zhong, Jingdi Yu, Yufei Tang, Qunyi Guo

  • June 18, 2026

Related Content

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence